Non-A, Non-B Hepatitis after Open-Heart Surgery in Sweden

Grillner, Lena; Bergdahl, Susanne; Jyrälä, Aarne

doi:10.3109/inf.1982.14.issue-3.03

Cited by 31 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was also the case in the present study, where 35% of the patients were totally asymptomatic and 59% were anicteric. Similar conclusions were drawn in two earlier prospective studies on PTH frequency after open-heart surgery in Scandinavia (11,12). Yet, a large proportion of PTH NANB patients seem to develop chronic hepatitis with prolonged periods of raised aminotransferases (2, 6,7,11,12 In our study, two findings are of special interest.…”

Section: Discussionsupporting

confidence: 89%

Long‐term follow‐up of chronic post‐transfusion non‐A, non‐B hepatitis: clinical and histological outcome

Mattsson

Weiland

Glaumann

1988

Liver

View full text Add to dashboard Cite

~ A chart review of chronic hepatitis cases at the Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Stockholm, Sweden, revealed 37 patients with chronic non-A, non-B hepatitis, caused by blood transfusions or intravenous gammaglobulin infusions. They had been followed up long-term, mean 46 months (range 1&149). During the initial hepatitis episode most patients had been anicteric and 13/37 (35%) asymptomatic. Yet, the majority developed progressive liver disease with chronic active hepatitis, with or without histological signs of cirrhosis. Thus, l0/18 (56%) on whom a liver biopsy had been performed within 7-12 months had chronic active hepatitis, four (22%) with histological signs of cirrhosis, and of the five patients biopsied after 2 5 years of follow-up, three (60%) had histological signs of cirrhosis. Accordingly, as the duration of follow-up increases, an increasing number of patients with post-transfusion non-A, non-B hepatitis seem to develop cirrhosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Long‐term follow‐up of chronic post‐transfusion non‐A, non‐B hepatitis: clinical and histological outcome

Mattsson

Weiland

Glaumann

1988

Liver

View full text Add to dashboard Cite

show abstract

“…Other studies of transfusion recipients in the USA have described incidences varying from 5.4 to 27.1 % [3]. Reported incidences in Europe are equally varied: 19% in Sweden [4], 13.8% in Italy [5], 3.4% in the Neth erlands [6] and 3.9% and 2.4% in the UK [7,8],…”

Section: Introductionmentioning

confidence: 99%

Post-Transfusion Non-A, Non-B Hepatitis: Significance of Raised ALT and Anti-HBc in Blood Donors

Gillon¹,

Hussey²,

Howe³

et al. 1988

Vox Sanguinis

View full text Add to dashboard Cite

The FDA has recommended that all blood collected in the USA should be screened for antibody to hepatitis B core antigen (anti-HBc) and for raised alanine aminotransferase (ALT) as possible indicators of non-A, non-B hepatitis carriage. As part of an assessment of the medical and economic implications of such a screening programme, we have screened 1,742 regular blood donors for ALT and 2,086 (including the same 1,742) for anti-HBc. 42 (2.4%) of the 1,742 donors had ALT levels above 45 units/l. Clinical assessment of 33 of these revealed that 26 exceeded their ideal body weight by more than 10% and 15 by more than 20%. 11 admitted to an alcohol intake of over 40 g daily. In all, 82% of donors with raised ALT had a ‘non-viral’ clinical explanation for this abnormality. Anti-HBc was detected in 42 (2.0%) of the 2,086 donors screened. 27 (64%) also had anti-HBs, and 11 (26%) had anti-HBe. There was no overlap between donors with raised ALT and those with anti-HBc. Combined screening would lead to a loss of at least 4.4% of donations in the population studied. In view of the medical and economic implications of the introduction of these screening tests, and the poverty of data on the clinical significance of post-transfusion non-A, non-B hepatitis, we conclude that such a screening programme cannot be justified at present. Further studies are required, including a prospective controlled trial of the effects of screening.

show abstract

“…Hepatitis C virus (HCV), a single-stranded enveloped RNA virus, has recently been identified as the major cause of NANBH [1,2]. Although acute NANBH is often subclinical, the disease progresses to chronic hepatitis in up to 50% of all cases [3,4]. Progression to chronic hepatitis seems to be even more common in patients with confirmed HCV infection [5].…”

Section: Introductionmentioning

confidence: 99%

Seroconversion to Hepatitis C Virus in Dialysis Patients: A Retrospective and Prospective Study

Medin¹,

Allander²,

Roll

et al. 1993

Nephron

Self Cite

View full text Add to dashboard Cite

The prevalence and incidence of hepatitis C virus (HCV) infections were studied in 236 dialysis patients and related to clinical data at two hospitals in Stockholm, Sweden. Patients were followed during 12 months and tested by 1st- and 2nd-generation anti-HCV assays. Time of seroconversion to HCV could be determined by retrospective analysis of stored serum samples. A total of 36 (15%) patients were anti-HCV positive. Time of seroconversion could be determined for 23 patients and was in the majority of cases associated with blood transfusions, but late seroconversion (more than 6 months after transfusion) as well as lack of transfusion in some cases implied that HCV might be transmitted through dialysis equipment. Persistence of elevated alanine amino-transferase levels for more than 6 months occurred in 17% of anti-HCV-positive patients. In conclusion, routes of transmission in dialysis units have to be further evaluated since routes other than transfusion may occur and diagnosis may be delayed in this group of patients probably due to a poor immunological response.

show abstract

Non-A, Non-B Hepatitis after Open-Heart Surgery in Sweden

Cited by 31 publications

References 20 publications

Long‐term follow‐up of chronic post‐transfusion non‐A, non‐B hepatitis: clinical and histological outcome

Long‐term follow‐up of chronic post‐transfusion non‐A, non‐B hepatitis: clinical and histological outcome

Post-Transfusion Non-A, Non-B Hepatitis: Significance of Raised ALT and Anti-HBc in Blood Donors

Seroconversion to Hepatitis C Virus in Dialysis Patients: A Retrospective and Prospective Study

Contact Info

Product

Resources

About